"Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda" EAD, Sofia
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Georgieva, Svetlana
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Checkmark [VIRTUAL] MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with hi.…
Recruiting
3
430
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groupbs
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
07/22
09/23
Orechkov, Krassimir
SELECT, NCT04549025 / 2019-004953-96: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Checkmark [VIRTUAL] Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
Checkmark Data from SELECT trial in combination with JTX-4014 for NSCLC at ASCO 2021
Recruiting
2
75
Europe, RoW
JTX-4014, Vopratelimab, JTX-2011
Jounce Therapeutics, Inc.
NSCLC
12/21
03/23

Download Options